Medscape To Develop FDA Biosimilars Educational Program

Courses Will Be Created To Enhance HCPs’ Understanding Of Biosimilars

Medscape Education has been awarded an FDA contract to develop an educational program about biosimilars for US healthcare professionals, which is set to launch in spring this year.

Doctors having lecture and taking notes in meeting room
Pharmacists' understanding of biosimilars is becoming increasingly crucial as more interchangeable products reach the US market • Source: Alamy

Medscape Education, a continuous professional development firm for healthcare professionals that is part of the WebMD network, has been awarded a contract from the US Food and Drug Administration to develop an educational curriculum and outreach programs on the use of biosimilars in medical practice.

The program of accredited continuing education courses for physicians, pharmacists and nurses will cover a broad range of topics on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports

 

Following the filing acceptance in the UK earlier this year, Kashiv and its three commercial musketeers – Alvotech, Advanz Pharma, and Amneal – are getting ready for applications in the US and Europe.

Formycon Signs US-Canada Deal With Valorum Biologics For Eylea Biosimilar

 

Formycon continues to expand its partnership network with a fresh deal for its aflibercept biosimilar in the US and Canada. At the same time, the firm has received a high demand for its corporate bonds, leading to early offering closure.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By 

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By 

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

More from Products

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By 

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

Cigna Claims BMS Tied Revlimid Settlements to Pomalyst ‘Pay-for-Delay’ Scheme

 
• By 

Among other schemes, Cigna alleges that Celgene and parent Bristol Myers Squibb “paid” generic challengers – via lucrative Revlimid profit-sharing agreements – to delay generic market entry for Pomalyst until 2026, unlawfully extending their monopoly and overcharging purchasers.

US Supreme Court Requests Solicitor General Input On Hikma Skinny Label Case

 
• By 

The US Supreme Court is seeking a brief “expressing the views of the United States,” following the US Federal Circuit’s decision to reopen Amarin’s claim of induced infringement against Hikma relating to its ‘skinny-label’ generic Vascepa (icosapent ethyl) product.